86% nocturia reduction in Direct-to-Bladder clinical trial.
This research by Dr Luna-Rivera is one of many pieces of evidence that Direct-to-Bladder therapies can produce better outcomes than taking the drug orally.
The most notable parts in this article are:
Nocturia (passing urine in the night) decreased after 10 doses of bladder instillation.
Urinary urgency reduced by 86%.
Oral antimuscarinics are the first line of treatment but not always effective, …and have been associated with adverse effects that limit their use.
This clinical trial show almost no presence of undesirable side effects, in addition to a notable improvement in quality-of-life.
We’ll be very interested in your feedback and questions
See the Market Opportunity https://www.uropharma.com/market-opportunity
See The Problem https://www.uropharma.com/the-problem
See The Solution https://www.uropharma.com/the-solution
See professionals’ testimonials https://www.uropharma.com/testimonials
Investors: contact us at firstname.lastname@example.org